Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid ...
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoi...
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT00171639
- Locations
- 🇺🇸
Southern AZ VA Health Care System, Tucson, Arizona, United States
🇺🇸Washington VA Medical Center, Washington, District of Columbia, United States
🇺🇸VA Medical Center-Long Beach, Long Beach, California, United States
Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 116
- Registration Number
- NCT00172029
- Locations
- 🇹🇷
Novartis Investigative Site, Trabzon, Turkey
Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate
- Conditions
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2015-01-22
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT00151073
- Locations
- 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women
- Conditions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 455
- Registration Number
- NCT00145275
Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 2456
- Registration Number
- NCT00145327
- Locations
- 🇺🇸
Comprehensive Clinical Trials, LLC, West Palm Beach, Florida, United States
🇺🇸Maine Center for Osteoporosis Research and Education, Bangor, Maine, United States
🇺🇸Washington University Center for Clinical Studies, St. Louis, Missouri, United States
Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2016-09-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 581
- Registration Number
- NCT00132808
- Locations
- 🇺🇸
For information regarding facilities, please contact the Central Contact, E. Hanover, New Jersey, United States
Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta
- Conditions
- First Posted Date
- 2005-08-17
- Last Posted Date
- 2017-06-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 127
- Registration Number
- NCT00131118
- Locations
- 🇺🇸
UCLA Medical Center-Dept of Pediatric Nephrology, Los Angeles, California, United States
🇺🇸Intermountains Orthopedics, Boise, Idaho, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 97
- Registration Number
- NCT00130494
- Locations
- 🇪🇸
Spanish Breast Cancer Research Group (GEICAM), San Sebastián de los Reyes, Madrid, Spain
S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 6097
- Registration Number
- NCT00127205
The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients
- Conditions
- First Posted Date
- 2005-06-16
- Last Posted Date
- 2006-05-09
- Lead Sponsor
- Royal Prince Alfred Hospital, Sydney, Australia
- Target Recruit Count
- 100
- Registration Number
- NCT00114556
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.